Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Longitudinal autoantibody responses against tumor-associated antigens decrease in breast cancer patients according to treatment modality

Fig. 1

Representative antibody responses against ERBB2-rFc in patients diagnosed with ERBB2 positive breast cancer treated with Trastuzumab. Three longitudinal blood draws were collected, immediately before surgery, 6 and 12 months after surgery. Patients BC-018 and BC-019 were still receiving Trastuzumab therapy at their 12-month visit, and patients BC-082 and BC-149 discontinued Trastuzumab therapy prior to their 12-month visit

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us